ZAP70 and LPL Assessment by RealTime PCR Analysis
We used 25 ng of cDNA (produced by a standard reverse transcription) in a qPCR reaction with SYBR® Green PCR Master Mix (Life Technologies [Thermo Fisher Scientific Inc., Waltham, MA, USA]) and 0.32 mol/L of gene-specific forward and reverse primers (Invitrogen [Thermo Fisher Scientific]). We standardized all results using cyclophilin A (PPI) gene expression. The primer sequences used to amplify ZAP70, PPI and LPL are listed in the table below. Standard Real-Time PCR was performed on an ABI Prism 7900 HT (Applied Biosystems [Thermo Fisher Scientific]). A calibrator sample (cDNA from the Namalwa cell line, a human B-lymphoid leukemia cell line that expresses ZAP70 at a low level; ATCC) was included as a control in each experiment. In all cases, we created dissociation curves to confirm PCR specificity. Data were analyzed using the comparative ΔΔCq method. See table at the bottom of this page.
CD38 Assessment by Flow Cytometry (FC)
We evaluated the cell surface expression of CD38 by FC in a CD19+ gate with a panel of fluorochrome-labeled monoclonal antibodies (phycoerythrinconjugated CD38, Cyanine-5 CD19, Immunotech [Beckman Coulter, Marseille, France]). CD38 expression was deemed positive if 7% of the cells stained positive in a standard 3-color FC analysis. This cut-off was calculated using ROC curve analysis maximizing the concordance with IgHV mutational status (1).
sCD23 and Beta-2-Microglobulin by ELISA Immunoassay
sCD23 and beta-2-microglobulin serum levels were determined using commercial immunoassay kits (Life Technologies [Thermo Fisher Scientific] and RayBiotech, Norcross, GA, USA). Standards were used to fully quantify the sCD23 or β2-microglobulin level, and the provided controls were loaded in each experiment to monitor the assay performance and the inter-assay variability.
Lymphocyte Doubling Time Assessment
Lymphocyte doubling time was determined as described by Montserrat et al. (3) and is defined as the time needed to double the peripheral lymphocyte count.
Cytogenetic Abnormalities Assessment
For conventional cytogenetic analysis, culture conditions, harvesting, slide preparation, and G-banding were carried out as described previously (4) . Additional cytogenetic abnormalities were investigated with the Chromoprobe Multiprobe® -CLL System. Fresh or frozen CLL cells were washed twice with PBS and incubated in KCl (0.075M -pH7) for 10 min. Cells were then fixed with Carnoy's Fixative (3:1 methanol: glacial acetic acid). Hybridization was performed according to the manufacturer's recommendation 
IgHV Gene Mutational Analysis
IgHV gene mutational analysis was performed with IGH Somatic Hypermutation Assay v2.0 (Invivoscribe, La Ciota, France) and sequences were aligned with those in the international ImMunoGeneTics information system database (http://imgt.cines.fr). Sequences with ≤ 2% deviation from any germ line IgHV sequence were considered unmutated (5).
SUPPLEMENTARY TEXT 2

Cellular and Serum RNA Extraction
Total cellular RNA was extracted from purified CD19+ cells in a single step using 800 μl of TriPure Isolation Reagent/300 μl of chloroform (Roche Applied Science, Vilvoorde, Belgium). For serum RNA, sera were first homogenized, and 350 μl was centrifuged at 300 g. From this, 250 μl was carefully recovered by pipetting in the middle, avoiding possible cellular debris (in the bottom) and lipid (in the superior phase), and extracted in a single step using 1 ml of Trizol LS reagent/300 μl of chloroform (Life Technologies [Thermo Fisher Scientific]). After denaturation, 25 fmol of a mixture of 2 synthesized Caenorhabditis elegans (cel) microRNA (cel-miR-39 and cel-miR-54, Integrated DNA Technologies, Leuven, Belgium) was spiked in as exogenous controls as previously described. For cellular and serum RNA extraction, aqueous phase recovery was performed using the PhaseLock system (Invitrogen) followed by isopropanol precipitation and two washings with 70% ethanol. RNA was dried and suspended in 30 μl and 100 μl of RNAse-free water for cellular and serum RNA, respectively.
SUPPLEMENTARY TEXT 3
Choice of Normalizer in Cells and Serum: RNU48 and miR- 16 For cellular microRNA normalization, a high number of studies validated the use of small nuclear RNA. In the present work, we performed a small study of RNU44 and RNU48 stability: based on 20 CLL patients, we obtained a mean cycle threshold (Cq) of 21.2 (standard deviation [SD] = 0.56) for RNU48 and a mean Cq of 23.0 (SD = 0.71) for RNU44. Because these two endogenous controls were very stable and gave similar results, RNU48 was used as the sole normalizer for cellular microRNA. In addition, mean Cq for RNU48 from our 273 CLL patients was 21.92 (SD =1.6).
No consensus for serum microRNA normalization exists, and several methods could be used, including the use of exogenous controls spiked-in after serum denaturation (6,7), miR-16 as an endogenous control (8, 9) , or absolute quantification based on RNA amount (10). Absolute quantification was abandoned because a classical spectrophotometer gives uninformative and inaccurate measures due to low serum RNA concentrations. While several studies described a remarkable stability of serum/plasma microRNA using exogenous controls, we observed a decrease of miR-150 amount after the first year of storage (Supplementary Figure S2) . Therefore, we decided to use a normalization based on an endogenous control. Based on our 252 CLL patient cohort, the mean Cq for miR-16 was 27.7 (SD = 2.1). A correlation between miR-150 and miR-16 also supports the use of miR-16 as an endogenous control (Supplementary Figure S2) . In addition, miR-16 Cq values were not significantly different among all prognostic factor-based subgroups (Supplementary Figure S3) , patient with or without deletion 13q (Supplementary Figure S4) , and between serum of healthy donors and CLL patients (Supplementary Figure S5) further supporting its use as a serum normalizer.
SUPPLEMENTARY TEXT 4 Decreased miR-150 and miR-16 in Frozen Sera across Time
According to Cq values (without any normalization), we observed that miR-16 and miR-150 expression decreased after the first year of storage (Supplementary Figures S2A-C) . In addition, when we normalized miR-16 and miR-150 with the mean of spiked-in exogenous controls (celmiR-39 and cel-miR-54), we confirmed the decrease of these serum microRNA (Supplementary Figures S2B-D). For this reason, exogenous controls could not be used for the normalization of retrospective studies. However, Cq values of miR-16 and miR-150 presented a significant correlation (r = 0.55, P < 0.0001), indicating that miR-16 could be used as an endogenous control (Supplemental Figure S2E) . Supplementary Table S1 . Correlation of cellular and serum miR-150 level with other markers and prognostic value. 
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Step Supplementary Figure S7 . Cellular and serum miR-150 are associated to absolute lymphocyte count. Cellular and serum miR-15 levels were measured by qPCR and were plotted with their median according to ALC. ALC was binarized using a cut-off of 26000 lymphocytes calculated using ROC curves. Statistical differences were assessed using the the Mann-Withney non-parametric test was used for other variables.
Supplementary Figure S8 . Serum miR-150 refines classical prognostic factors. TFS curves are shown for serum miR-150 status combined with Binet Stage (A), IgHV mutational status (B) and ZAP70 (C). Combination of these prognostic factors with serum miR-150 status could classify patients in different subgroup with decreased median TFS.
